Establishment Labs Holdings, Inc.

How big is Establishment Labs Holdings, Inc.?

As of Jun 18, Establishment Labs Holdings, Inc. has a market capitalization of 1,097.06 million and reported net sales of 170.24 million, with a net loss of 89.10 million over the latest four quarters.

As of Jun 18, Establishment Labs Holdings, Inc. has a market capitalization of 1,097.06 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 170.24 million for the latest four quarters. During the same period, the consolidated net profit was a loss of 89.10 million.<BR><BR>As of Dec 24, the company's shareholder's funds were 53.10 million, and total assets amounted to 346.83 million.

What does Establishment Labs Holdings, Inc. do?

Establishment Labs Holdings, Inc. is a medical technology company specializing in breast aesthetics and reconstruction. As of March 2025, it reported net sales of $41 million and a net loss of $21 million, with a market cap of approximately $1.1 billion.

Overview: <BR>Establishment Labs Holdings, Inc. is a medical technology and aesthetics company focused on patient safety and aesthetic outcomes in the breast aesthetics and reconstruction market.<BR><BR>Financial Snapshot: <BR>Net Sales: 41 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -21 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,097.06 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 3.96 <BR>Return on Equity: -231.14% <BR>Price to Book: 28.46<BR><BR>Contact Details: <BR>Address: Building B15 and 25, Coyol Free Zone, ALAJUELA None: VG1110 <BR>Tel: ['506 2 4342400', '1 949 4476671'] <BR>Website: https://establishmentlabs.com

Should I buy, sell or hold Establishment Labs Holdings, Inc.?

Who are in the management team of Establishment Labs Holdings, Inc.?

As of March 2022, the management team of Establishment Labs Holdings, Inc. includes Chairman Nicholas Lewin, CEO Juan Jose Chacon Quiros, and several independent directors: Lisa Colleran, Dennis Condon, Lisa Gersh, David Hung, and Edward Schutter. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Establishment Labs Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Nicholas Lewin, Chairman of the Board<BR>- Mr. Juan Jose Chacon Quiros, Chief Executive Officer and Director<BR>- Ms. Lisa Colleran, Independent Director<BR>- Mr. Dennis Condon, Independent Director<BR>- Ms. Lisa Gersh, Independent Director<BR>- Dr. David Hung, Independent Director<BR>- Mr. Edward Schutter, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Establishment Labs Holdings, Inc. overvalued or undervalued?

Establishment Labs Holdings, Inc. is currently considered risky and overvalued due to a negative P/E ratio and poor return metrics, with a year-to-date return of -11.98%, significantly underperforming the S&P 500's 12.22%.

As of 20 March 2019, Establishment Labs Holdings, Inc. moved from a grade of does not qualify to risky, indicating a deterioration in its valuation outlook. The company appears to be overvalued, particularly given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 28.91, an EV to EBIT of -21.81, and an EV to EBITDA of -25.67, all of which suggest significant challenges in generating profits relative to its valuation.<BR><BR>In comparison to its peers, Establishment Labs has a P/E ratio of -12.69, while TransMedics Group, Inc. is fairly valued with a P/E of 50.23, and Veracyte, Inc. is considered expensive with a P/E of 50.97. The company's recent stock performance reflects its struggles, with a year-to-date return of -11.98% compared to the S&P 500's 12.22%, highlighting the underperformance relative to the broader market.

Is Establishment Labs Holdings, Inc. technically bullish or bearish?

As of October 31, 2025, Establishment Labs Holdings, Inc. has a mildly bullish technical trend, supported by positive moving averages and MACD, despite underperforming the S&P 500 over the past week and year-to-date.

As of 31 October 2025, the technical trend for Establishment Labs Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands and KST also indicate a mildly bullish stance on both weekly and monthly time frames. Daily moving averages are bullish, suggesting short-term strength. However, the RSI shows no signal on both weekly and monthly charts, indicating a lack of momentum confirmation. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and year-to-date, but it has outperformed the index over the past month. Overall, the current technical stance is mildly bullish, driven by positive indicators in moving averages and MACD, despite some mixed signals in other metrics.